This article has been cited by
1Mechanism of action of suvorexant
Stephen M. Stahl
CNS Spectrums.2016;21(3)215
[DOI]
2Using Human Genetics to Drive Drug Discovery: A Perspective
Caroline S. Fox
American Journal of Kidney Diseases.2019;74(1)111
[DOI]
3One-pot reaction for the synthesis of N -substituted 2-aminobenzoxazoles using triphenylbismuth dichloride as cyclodesulfurization reagent
Yuki Murata,Natsuho Matsumoto,Maya Miyata,Yuki Kitamura,Naoki Kakusawa,Mio Matsumura,Shuji Yasuike
Journal of Organometallic Chemistry.2018;859(1)18
[DOI]
4Improvement of glycemic control by treatment for insomnia with suvorexant in type 2 diabetes mellitus
Norikazu Toi,Masaaki Inaba,Masafumi Kurajoh,Tomoaki Morioka,Noriyuki Hayashi,Tomoe Hirota,Daichi Miyaoka,Masanori Emoto,Shinsuke Yamada
Journal of Clinical & Translational Endocrinology.2019;15(1)37
[DOI]
5From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in Dogs
Christine Brotschi,Martin H. Bolli,John Gatfield,Bibia Heidmann,Francois Jenck,Catherine Roch,Thierry Sifferlen,Alexander Treiber,Jodi T. Williams,Christoph Boss
ChemMedChem.2020;15(5)430
[DOI]
6Obesity and Circadian Cycle of Sleep and Wakefulness: Common Points and Prospects of Therapy
O. N. Berdina,I. M. Madaeva,L. V. Rychkova
Acta Biomedica Scientifica.2020;5(1)21
[DOI]
7Sleep and its' disturbanses in chronic obstructive pulmonary disease
A. D. Palman
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2018;118(4)113
[DOI]
8Crystal Structures of Human Orexin 2 Receptor Bound to the Subtype-Selective Antagonist EMPA
Ryoji Suno,Kanako Terakado Kimura,Takanori Nakane,Keitaro Yamashita,Junmei Wang,Takaaki Fujiwara,Yasuaki Yamanaka,Dohyun Im,Shoichiro Horita,Hirokazu Tsujimoto,Maki S. Tawaramoto,Takatsugu Hirokawa,Eriko Nango,Kensuke Tono,Takashi Kameshima,Takaki Hatsui,Yasumasa Joti,Makina Yabashi,Keiko Shimamoto,Masaki Yamamoto,Daniel M. Rosenbaum,So Iwata,Tatsuro Shimamura,Takuya Kobayashi
Structure.2018;26(1)7
[DOI]
9Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
Taro Kishi,Shinji Matsunaga,Nakao Iwata,Gianni Virgili
PLOS ONE.2015;10(8)e0136910
[DOI]
10UPLC-MS/MS determination of suvorexant in urine by a simplified dispersive liquid-liquid micro-extraction followed by ultrasound assisted back extraction from solidified floating organic droplets
Muzaffar Iqbal,Essam Ezzeldin,Nasr Y. Khalil,Prawez Alam,Khalid A. Al-Rashood
Journal of Pharmaceutical and Biomedical Analysis.2019;164(8)1
[DOI]
11Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders
Ying Han,Kai Yuan,Yongbo Zheng,Lin Lu
Neuroscience Bulletin.2019;164(8)1
[DOI]
12Simple and Highly Sensitive UPLC-ESI-MS/MS Assay for Rapid Determination of Suvorexant in Plasma
Muzaffar Iqbal,Essam Ezzeldin,Nasr Y. Khalil,Sara T. A. Al-Rashood,Khalid A. Al-Rashood
Journal of Analytical Toxicology.2016;164(8)1
[DOI]
13Tissue Distribution of Suvorexant in Three Forensic Autopsy Cases
Brian Waters,Kenji Hara,Natsuki Ikematsu,Mio Takayama,Aya Matsusue,Masayuki Kashiwagi,Shin-ichi Kubo
Journal of Analytical Toxicology.2018;42(4)276
[DOI]
14Pharmacological profiling of zebrafish behavior using chemical and genetic classification of sleep-wake modifiers
Yuhei Nishimura,Shiko Okabe,Shota Sasagawa,Soichiro Murakami,Yoshifumi Ashikawa,Mizuki Yuge,Koki Kawaguchi,Reiko Kawase,Toshio Tanaka
Frontiers in Pharmacology.2015;6(4)276
[DOI]
15Hypocretins, Neural Systems, Physiology, and Psychiatric Disorders
Shi-Bin Li,Jeff R. Jones,Luis de Lecea
Current Psychiatry Reports.2016;18(1)276
[DOI]
16Neuropeptide modulation of addiction: Focus on galanin
Shannyn G. Genders,Karlene J. Scheller,Elvan Djouma
Neuroscience & Biobehavioral Reviews.2020;110(1)133
[DOI]
17The neuropeptide genes SST, TAC1, HCRT, NPY, and GAL are powerful epigenetic biomarkers in head and neck cancer: a site-specific analysis
Kiyoshi Misawa,Masato Mima,Atsushi Imai,Daiki Mochizuki,Yuki Misawa,Shiori Endo,Ryuji Ishikawa,Takeharu Kanazawa,Hiroyuki Mineta
Clinical Epigenetics.2018;10(1)133
[DOI]
18Sleep Disorders in Patients With Posttraumatic Stress Disorder
Ali A. El-Solh,Usman Riaz,Jasmine Roberts
Chest.2018;154(2)427
[DOI]
19Characterization of Five Oxidative Degradation Impurities and One Process Impurity of Suvorexant Drug Substance by LC-MS/MS, HR-MS and 1D, 2D NMR: Validation of Suvorexant Drug Substance and Process Impurities by HPLC and UPLC
Nagaraju Rajana,Dharamasoth Rama Devi,Dinne Naresh Kumar Reddy,J Moses Babu,K Basavaiah,K Balakumaran
Journal of Chromatographic Science.2020;154(2)427
[DOI]
20Sleep modulating agents
Younggi Choi,Brian K. Raymer
Bioorganic & Medicinal Chemistry Letters.2019;29(16)2025
[DOI]
21Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure–Activity Relationships, and Sleep-Promoting Properties in Rats
Christine Brotschi,Catherine Roch,John Gatfield,Alexander Treiber,Jodi T. Williams,Thierry Sifferlen,Bibia Heidmann,Francois Jenck,Martin H. Bolli,Christoph Boss
ChemMedChem.2019;14(13)1257
[DOI]
22Effect of suvorexant on nighttime blood pressure in hypertensive patients with insomnia: The SUPER-1 study
Kazuomi Kario,Koichiro Yamasaki,Kazuro Yagi,Masatoshi Tsukamoto,Shoji Yamazaki,Yukie Okawara,Naoko Tomitani,Hiroshi Kanegae
The Journal of Clinical Hypertension.2019;21(7)896
[DOI]
23Effect of suvorexant on nighttime blood pressure in hypertensive patients with insomnia: The SUPER-1 study
Mark D. Tricklebank
The Journal of Clinical Hypertension.2019;21(7)181
[DOI]
24Chronobesity: role of the circadian system in the obesity epidemic
J. Laermans,I. Depoortere
Obesity Reviews.2016;17(2)108
[DOI]
25Ultrasound-assisted synthesis of substituted 2-aminobenzimidazoles, 2-aminobenzoxazoles, and related heterocycles
Wong Phakhodee,Chuthamat Duangkamol,Nittaya Wiriya,Mookda Pattarawarapan
Tetrahedron Letters.2016;57(47)5290
[DOI]
  Feedback 
  Subscribe